Novavax, one of the worst performers on Wall Street, and that is after an FDA warning on its COVID vaccine. Year to date, down 68 percent. Of course, that coming as a result of the FDA out with their analysis from Novavax’s data that they submitted for the emergency use filing for the meeting coming up on June 7th. The advisory committee to the FDA is going to be weighing all this information and deciding whether or not to recommend Novavax’s vaccine. We saw in that report today from the FDA saying, “Multiple events of myocarditis/pericarditis were reported in temporal relationships to NVX-CoV2373 administration following mRNA COVID-19 vaccines and raising concern for a causal relationship to NVX-CoV2373.”
If you would like to receive an e-mail notice of the most recent articles published in The Vaccine Reaction each week, click here.
